LATEST NEWS

Bristol Myers Squibb Receives European Commission Approval for Zeposia (ozanimod) for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease

-Bristol Myers Squibb has announced that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple...

Read More

Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending approval...

Read More

Phase III ADAURA trial showed treatment with Tagrisso after surgery with curative intent reduced the risk of disease recurrence or death by c. 80%

Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the...

Read More

Thermo Fisher Scientific and CSL Enter Strategic Partnership to Provide Best-in-Class Pharma Services

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and global biotechnology company, CSL Limited (ASX:CSL;USOTC:CSLLY) today announced they have entered into...

Read More

Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the Colorado Center for Personalized Medicine (CCPM) at the University of Colorado Anschutz Medical Campus recently announced a...

Read More

Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies

Gilead Sciences, Inc. (NASDAQ: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today that...

Read More

Multimedia

 Tweets

  • Precision MedicineNew post: Bristol Myers Squibb Receives European Commission Approval for Zeposia (ozanimod) for the Treatment of ,
  • Precision MedicineNew post: Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA ,
  • Precision MedicineNew post: Phase III ADAURA trial showed treatment with Tagrisso after surgery with curative intent reduced the risk ,
  • Precision MedicineNew post: Thermo Fisher Scientific and CSL Enter Strategic Partnership to Provide Best-in-Class Pharma Services ,

Subscribe now to receive your FREE copy of The Journal of Precision Medicine